WONDFO BIOTECH(SZ:300482) Mei Ri Jing Ji Xin Wen·2025-10-27 15:31Core Viewpoint - Wanfu Biological reported a significant decline in revenue and profit for the first nine months of 2025, attributing the downturn to a sluggish IVD industry and ongoing policy impacts [1][2]. Financial Performance - For the first nine months of 2025, the company achieved revenue of 1.69 billion yuan, a year-on-year decrease of 22.52%, and a net profit attributable to shareholders of 134 million yuan, down 69.32% [1]. - In Q3 2025, revenue was 445 million yuan, a decline of 26.66%, with a net loss of 55.46 million yuan, representing a drastic year-on-year decrease of 169.21% [1]. - The net cash flow from operating activities was 52.71 million yuan, down 69.59% year-on-year, and basic earnings per share fell by 70.21% to 0.28 yuan [1][2]. Asset and Liability Adjustments - As of the end of the reporting period, cash and cash equivalents stood at 205 million yuan, a decrease of 75.24% from the beginning of the year, primarily due to investments in fixed and intangible assets and dividend payments [2]. - Accounts receivable amounted to 1.046 billion yuan, down 69 million yuan from the beginning of the year, influenced by policy pressures in the IVD industry [2]. - The balance of construction in progress surged by 183.86% to 14.54 million yuan, driven by investments in the Songshan Lake and Knowledge City production bases [2]. Business Strategy and Adjustments - The company has initiated a share repurchase plan, aiming to buy back shares worth between 30 million and 60 million yuan to support employee stock ownership plans [3]. - Wanfu Biological has designated 2025 as a year for business adjustments, focusing on stabilizing its fluorescence business and expanding its market presence in the chemical luminescence sector [3][4]. - The company plans to enhance its international market presence by introducing new technology platforms and expanding its product lines in overseas markets [4][5].